Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report)’s stock price reached a new 52-week low on Friday following a weaker than expected earnings announcement. The company traded as low as $12.46 and last traded at $13.04, with a volume of 30317 shares. The stock had previously closed at $13.88.
The company reported ($3.38) earnings per share for the quarter, missing the consensus estimate of ($2.68) by ($0.70).
Analyst Ratings Changes
Several equities research analysts have weighed in on the company. Stifel Nicolaus assumed coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating and a $32.00 target price on the stock. TD Cowen assumed coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating on the stock. Finally, Guggenheim assumed coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They issued a “buy” rating and a $45.00 target price on the stock.
Sionna Therapeutics Price Performance
Sionna Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
See Also
- Five stocks we like better than Sionna Therapeutics
- What Are Dividend Challengers?
- FedEx Delivers Another Crushing Blow to Its Stock Price
- How to Capture the Benefits of Dividend Increases
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- What is a support level?
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
